Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Deerfield Healthcare Technology Acquisitions Corp. Announces Proposal to Form CareMax
Progenity Announces Closing of Public Offering of Common Stock
Progenity Announces Closing of Convertible Senior Notes Offering
Amryt Announces $40M Private Placement with Leading Biotech Investors
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
BioCryst Announces FDA Approval of ORLADEYO™ (Berotralstat) for Hereditary Angiodema
Alcresta Therapeutics’ RELiZORB® (Immobilized Lipase) Cartridge Shows Long-Term Effectiveness
We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Privacy Policy. By closing this message box or continuing to use our website you consent to our use of cookies.
